AAAAAA
Results: 1-25/35
Authors:
SRIVASTAVA SC
ATKINS HL
KRISHNAMURTHY GT
ZANZI I
SILBERSTEIN EB
MEINKEN G
MAUSNER LF
SWAILEM F
DALESSANDRO T
CABAHUG CJ
LAU Y
PARK T
MADAJEWICZ S
Citation: Sc. Srivastava et al., TREATMENT OF METASTATIC BONE PAIN WITH TIN-117M STANNIC DIETHYLENETRIAMINEPENTAACETIC ACID - A PHASE I II CLINICAL-STUDY/, Clinical cancer research, 4(1), 1998, pp. 61-68
Authors:
SRIVASTAVA SC
ATKINS HL
KRISHNAMURTHY GT
ZANZI I
SILBERSTEIN EB
MEINKEN G
MAUSNER LF
SWAILEM F
DALESSANDRO T
CABAHUG CJ
LAU Y
PARK T
MADAJEWICZ S
Citation: Sc. Srivastava et al., TREATMENT OF METASTATIC BONE PAIN WITH TIN-117M STANNIC DIETHYLENETRIAMINEPENTAACETIC ACID - A PHASE I II CLINICAL-STUDY/, Clinical cancer research, 4(1), 1998, pp. 61-68
Authors:
SILBERSTEIN EB
Citation: Eb. Silberstein, DRUG LABELING CHANGES, The Journal of nuclear medicine, 39(10), 1998, pp. 1831-1831
Authors:
GLECKLER M
VALENTINE JD
SILBERSTEIN EB
Citation: M. Gleckler et al., CALCULATING LENS DOSE AND SURFACE DOSE-RATES FROM SR-90 OPHTHALMIC APPLICATORS USING MONTE-CARLO MODELING, Medical physics, 25(1), 1998, pp. 29-36
Authors:
FRANCO RS
LOHMANN J
SILBERSTEIN EB
MAYFIELDPRATT G
PALASCAK M
NEMETH TA
JOINER CH
WEINER M
RUCKNAGEL DL
Citation: Rs. Franco et al., TIME-DEPENDENT CHANGES IN THE DENSITY AND HEMOGLOBIN-F CONTENT OF BIOTIN-LABELED SICKLE CELLS, The Journal of clinical investigation, 101(12), 1998, pp. 2730-2740
Authors:
SILBERSTEIN EB
Citation: Eb. Silberstein, SAMARIUM SM-153 LEXIDRONAM - A VIEWPOINT, Drugs & aging, 11(5), 1997, pp. 419-419
Authors:
LIVINGSTON GK
JENSEN RH
SILBERSTEIN EB
HINNEFELD JD
PRATT G
BIGBEE WL
LANGLOIS RG
GRANT SG
SHUKLA R
Citation: Gk. Livingston et al., RADIOBIOLOGICAL EVALUATION OF IMMIGRANTS FROM THE VICINITY OF CHERNOBYL, International journal of radiation biology, 72(6), 1997, pp. 703-713
ADVERSE REACTIONS TO RADIOPHARMACEUTICALS - THE SNM RSNA USP DRUG PRODUCT PROBLEM REPORTING PROGRAM/
Authors:
SILBERSTEIN EB
Citation: Eb. Silberstein, ADVERSE REACTIONS TO RADIOPHARMACEUTICALS - THE SNM RSNA USP DRUG PRODUCT PROBLEM REPORTING PROGRAM/, The Journal of nuclear medicine, 38(9), 1997, pp. 49-49
Authors:
BARTOLD SP
DONOHOE KJ
FLETCHER JW
HAYNIE TP
HENKIN RE
SILBERSTEIN EB
ROYAL HD
VANDENABBEELE A
Citation: Sp. Bartold et al., PROCEDURE GUIDELINE FOR GALLIUM SCINTIGRAPHY IN THE EVALUATION OF MALIGNANT DISEASE, The Journal of nuclear medicine, 38(6), 1997, pp. 990-994
Authors:
WEILAND FL
CARRETTA RF
HOLDER LE
SILBERSTEIN EB
DANN RW
MADSEN KS
ATEN EM
Citation: Fl. Weiland et al., TC-99M P280 DETECTION OF DEEP VENOUS THROMBOSIS (DVT) IN PATIENTS WITH A PRIOR HISTORY OF DVT, The Journal of nuclear medicine, 38(5), 1997, pp. 362-362
Authors:
WEILAND FL
CARRETTA RF
HOLDER LE
SILBERSTEIN EB
DANN RW
MADSEN KS
ATEN EM
Citation: Fl. Weiland et al., SAFETY AND EFFICACY OF TC-99M P280 FOR THE DETECTION AND LOCALIZATIONOF ACUTE DEEP VENOUS THROMBOSIS (DVT), The Journal of nuclear medicine, 38(5), 1997, pp. 364-364
Authors:
SILBERSTEIN EB
Citation: Eb. Silberstein, SAFETY STUDY OF PET RADIOPHARMACEUTICALS - RETROSPECTIVE AND PROSPECTIVE DATA, The Journal of nuclear medicine, 38(5), 1997, pp. 415-415
Authors:
SILBERSTEIN EB
Citation: Eb. Silberstein, ADVERSE REACTIONS TO RADIOPHARMACEUTICALS - THE RSNA-SNM-USP DRUG PRODUCT PROBLEM REPORTING PROGRAM, Radiology, 204(2), 1997, pp. 34-34
Authors:
WIKENHEISER KA
SILBERSTEIN EB
Citation: Ka. Wikenheiser et Eb. Silberstein, BONE-SCINTIGRAPHY SCREENING IN STAGE I-II BREAST-CANCER - IS IT COST-EFFECTIVE, Cleveland Clinic journal of medicine, 63(1), 1996, pp. 43-47
Authors:
SILBERSTEIN EB
SAEKS E
Citation: Eb. Silberstein et E. Saeks, INTENSE UPTAKE OF IN-111 SATUMOMAB PENDETIDE IN AN INFLAMMATORY MASS, Clinical nuclear medicine, 21(1), 1996, pp. 53-55
Authors:
DONOHOE K
BRILL AB
BRILL DR
CONWAY JJ
SILBERSTEIN EB
WHIPPLE C
Citation: K. Donohoe et al., HOW TO BE AN EFFECTIVE RISK COMMUNICATOR .2., The Journal of nuclear medicine, 37(7), 1996, pp. 20-22
Authors:
DONOHOE KJ
BRILL AB
BRILL DR
CONWAY JJ
SILBERSTEIN EB
WHIPPLE C
Citation: Kj. Donohoe et al., HOW TO BE AN EFFECTIVE RISK COMMUNICATOR .1., The Journal of nuclear medicine, 37(6), 1996, pp. 23
Authors:
SILBERSTEIN EB
STUBBS J
EVANS J
ATKINS H
Citation: Eb. Silberstein et al., CORRELATION OF MARROW SUPPRESSION WITH MARROW ABSORBED DOSE PARAMETERS, SN-117M DTPA, The Journal of nuclear medicine, 37(5), 1996, pp. 398-398
Authors:
SILBERSTEIN EB
Citation: Eb. Silberstein, DOSAGE AND RESPONSE IN RADIOPHARMACEUTICAL THERAPY OF PAINFUL OSSEOUSMETASTASES, The Journal of nuclear medicine, 37(2), 1996, pp. 249-252
Authors:
SILBERSTEIN EB
RYAN J
Citation: Eb. Silberstein et J. Ryan, PREVALENCE OF ADVERSE REACTIONS IN NUCLEAR-MEDICINE, The Journal of nuclear medicine, 37(1), 1996, pp. 185-192
Authors:
FRANCO RS
LOHMANN J
SILBERSTEIN EB
MAYFIELDPRATT G
RUCKNAGEL DL
JOINER CH
WEINER M
Citation: Rs. Franco et al., THE USE OF BIOTINYLATED RBC TO DETERMINE THE IN-VIVO SURVIVAL CHARACTERISTICS OF NORMAL AND SICKLE CELLS, Blood, 88(10), 1996, pp. 33-33
Authors:
ELGAZZAR AH
SILBERSTEIN EB
HUGHES J
Citation: Ah. Elgazzar et al., PERFUSION AND VENTILATION SCANS IN PATIENTS WITH EXTENSIVE OBSTRUCTIVE AIRWAY DISEASE - UTILITY OF SINGLE-BREATH (WASHIN) XE-133, The Journal of nuclear medicine, 36(1), 1995, pp. 64-67
Authors:
SILBERSTEIN EB
WILLIAMS C
Citation: Eb. Silberstein et C. Williams, SR-89 THERAPY FOR PAINFUL OSSEOUS METASTASES - ACTIVITY-RESPONSE RELATIONSHIP, The Journal of nuclear medicine, 35(5), 1994, pp. 160000036-160000036
Authors:
SILBERSTEIN EB
Citation: Eb. Silberstein, PHOSPHATE AND ETIDRONATE CYCLIC TREATMENT OF OSTEOPOROSIS MONITORED WITH GD-153 DUAL-PHOTON ABSORPTIOMETRY (DPA), The Journal of nuclear medicine, 35(5), 1994, pp. 160000090-160000090
Authors:
SILBERSTEIN EB
NAGARAJ N
Citation: Eb. Silberstein et N. Nagaraj, IS I-131 MISADMINISTRATION A PROBLEM - ANALYSIS OF NRC RECORDS 1981-1990 AND IMPLICATIONS FOR QUALITY MANAGEMENT PROGRAMS (QMP), The Journal of nuclear medicine, 35(5), 1994, pp. 160000166-160000166